These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 10473107)

  • 1. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.
    Miknyoczki SJ; Chang H; Klein-Szanto A; Dionne CA; Ruggeri BA
    Clin Cancer Res; 1999 Aug; 5(8):2205-12. PubMed ID: 10473107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.
    Miknyoczki SJ; Dionne CA; Klein-Szanto AJ; Ruggeri BA
    Ann N Y Acad Sci; 1999 Jun; 880():252-62. PubMed ID: 10415871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
    George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
    Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.
    Weeraratna AT; Dalrymple SL; Lamb JC; Denmeade SR; Miknyoczki S; Dionne CA; Isaacs JT
    Clin Cancer Res; 2001 Aug; 7(8):2237-45. PubMed ID: 11489797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB.
    Evans AE; Kisselbach KD; Liu X; Eggert A; Ikegaki N; Camoratto AM; Dionne C; Brodeur GM
    Med Pediatr Oncol; 2001 Jan; 36(1):181-4. PubMed ID: 11464878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts.
    Evans AE; Kisselbach KD; Yamashiro DJ; Ikegaki N; Camoratto AM; Dionne CA; Brodeur GM
    Clin Cancer Res; 1999 Nov; 5(11):3594-602. PubMed ID: 10589776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice.
    Miknyoczki SJ; Wan W; Chang H; Dobrzanski P; Ruggeri BA; Dionne CA; Buchkovich K
    Clin Cancer Res; 2002 Jun; 8(6):1924-31. PubMed ID: 12060637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).
    Dionne CA; Camoratto AM; Jani JP; Emerson E; Neff N; Vaught JL; Murakata C; Djakiew D; Lamb J; Bova S; George D; Isaacs JT
    Clin Cancer Res; 1998 Aug; 4(8):1887-98. PubMed ID: 9717816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion.
    Bernacki RJ; Oberman EJ; Seweryniak KE; Atwood A; Bergeron RJ; Porter CW
    Clin Cancer Res; 1995 Aug; 1(8):847-57. PubMed ID: 9816054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.
    Festuccia C; Muzi P; Gravina GL; Millimaggi D; Speca S; Dolo V; Ricevuto E; Vicentini C; Bologna M
    Int J Oncol; 2007 Jan; 30(1):193-200. PubMed ID: 17143529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts.
    Pinski J; Weeraratna A; Uzgare AR; Arnold JT; Denmeade SR; Isaacs JT
    Cancer Res; 2002 Feb; 62(4):986-9. PubMed ID: 11861369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.
    Medicherla S; Li L; Ma JY; Kapoun AM; Gaspar NJ; Liu YW; Mangadu R; O'Young G; Protter AA; Schreiner GF; Wong DH; Higgins LS
    Anticancer Res; 2007; 27(6B):4149-57. PubMed ID: 18229422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trojan p16 peptide suppresses pancreatic cancer growth and prolongs survival in mice.
    Hosotani R; Miyamoto Y; Fujimoto K; Doi R; Otaka A; Fujii N; Imamura M
    Clin Cancer Res; 2002 Apr; 8(4):1271-6. PubMed ID: 11948142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
    Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
    Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo antineoplastic activity of a new platinum antineoplastic agent, (R)-(-)-1,1-cyclobutanedicarboxylate (2-aminomethylpyrrolidine)-platinum (II) (DWA2114R) on freshly separated human tumor cells and human tumor xenografts transplanted in nude mice--a comparison with cis-diammine-dichloroplatinum (CDDP).
    Nio Y; Imai S; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Tobe T
    Anticancer Res; 1991; 11(2):761-7. PubMed ID: 2064331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior.
    Miknyoczki SJ; Lang D; Huang L; Klein-Szanto AJ; Dionne CA; Ruggeri BA
    Int J Cancer; 1999 May; 81(3):417-27. PubMed ID: 10209957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo.
    Mishra R; Miyamoto M; Yoshioka T; Ishikawa K; Matsumura Y; Shoji Y; Ichinokawa K; Itoh T; Shichinohe T; Hirano S; Kondo S
    Int J Oncol; 2009 May; 34(5):1231-40. PubMed ID: 19360336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.